


Add the following:

▲Nateglinide



$C_{19}H_{27}NO_3$ 317.42
D-Phenylalanine, N-[[*trans*-4-(1-methylethyl)cyclohexyl]carbonyl]-;
(-)-N-[(*trans*-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine
[105816-04-4].

DEFINITION

Nateglinide contains NLT 98.0% and NMT 102.0% of $C_{19}H_{27}NO_3$, calculated on the dried basis.

IDENTIFICATION

- **A. INFRARED ABSORPTION** (197K)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• **PROCEDURE**

Buffer: 8.5 g/L of anhydrous dibasic sodium phosphate in water. Adjust with phosphoric acid to a pH of 7.5.

Mobile phase: Methanol and *Buffer* (1:1)

Standard solution: 1.0 mg/mL of nateglinide prepared as follows: transfer USP Nateglinide RS to a suitable volumetric flask, dissolve first in methanol, using 50% of the final volume, and then dilute with *Buffer* to volume.

System suitability stock solution: 0.2 mg/mL each of USP Nateglinide Related Compound C RS and DL-phenylalanine in methanol. [NOTE—Sonicate, if necessary.]

System suitability solution: Transfer USP Nateglinide RS to a suitable volumetric flask, dissolve first in methanol, using 45% of the final volume, add *System suitability stock solution* equal to 5% of the final volume, and then dilute with *Buffer* to volume to obtain a solution containing about 1.0 mg/mL of nateglinide and about 0.01 mg/mL each of nateglinide related compound C and DL-phenylalanine.

Sample solution: Transfer about 100 mg of Nateglinide to a 100-mL volumetric flask, dissolve in 50 mL of methanol, and dilute with *Buffer* to volume.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 6-mm × 15-cm; 6-μm packing L71 (see *Chromatographic Reagents* under *Reagents, Indicators, and Solutions*)

Column temperature: 30°

Flow rate: 1 mL/min

Injection size: 20 μL

System suitability

Samples: *Standard solution* and *System suitability solution*

Suitability requirements

Resolution: NLT 0.9 between nateglinide related compound C and nateglinide, *System suitability solution*

Relative standard deviation: NMT 1.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of nateglinide ($C_{19}H_{27}NO_3$) in the portion of Nateglinide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Nateglinide RS in the *Standard solution* (mg/mL)

C_U = concentration of Nateglinide in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

- **RESIDUE ON IGNITION** (281): NMT 0.1%
- **HEAVY METALS**, *Method II* (231): NMT 10 ppm

Change to read:

• **LIMIT OF NATEGLINIDE RELATED COMPOUND A AND OTHER IMPURITIES**

Buffer: 7.8 g/L of monobasic sodium phosphate in water.

Adjust with phosphoric acid to a pH of 2.5.

Mobile phase: Acetonitrile and *Buffer* (7:13)

Standard solution: Dissolve USP Nateglinide RS in acetonitrile to obtain a solution having a known concentration of about 0.3 mg/mL. Further dilute this solution with *Mobile phase* to obtain a solution having a known concentration of about 0.06 mg/mL.

System suitability stock solution: Dissolve USP Nateglinide Related Compound A RS in acetonitrile to obtain a solution containing about 0.6 mg/mL. Further dilute this solution with *Mobile phase* to obtain a solution containing about 0.12 mg/mL.

System suitability solution: Transfer an amount of USP Nateglinide RS to a suitable volumetric flask, dissolve first in acetonitrile using 10% of the final volume, then add *System suitability stock solution* equal to 10% of the final volume, and dilute with *Mobile phase* to volume to obtain a solution containing about 6 mg/mL of nateglinide and about 0.012 mg/mL of nateglinide related compound A.

Sample solution: Transfer 60 mg of Nateglinide to a 10-mL volumetric flask, dissolve in a minimal amount of (R81-Oct-2010) acetonitrile, and dilute with *Mobile phase* to volume.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 3.9-mm × 5-cm; 5-μm, packing L7

Column temperature: 40°

Flow rate: 2 mL/min

Injection size: 100 μL

Run time: 5 times the retention time of nateglinide

System suitability

Samples: *Standard solution* and *System suitability solution*

Suitability requirements

Resolution: NLT 2.5 between nateglinide related compound A and nateglinide, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Nateglinide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

2 Nateglinide

r_U = peak response of each impurity from the *Sample solution*
 r_S = peak response of nateglinide from the *Standard solution*
 C_S = concentration of USP Nateglinide RS in the *Standard solution* (mg/mL)
 C_U = concentration of Nateglinide in the *Sample solution* (mg/mL)
 F = relative response factor (see *Table 1*)

Acceptance criteria

Individual impurities: See *Table 1*.

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Nateglinide related compound A ^a	0.5	0.015	0.2
Ethyl analog ^b	0.6	1.0	0.1
Nateglinide	1.0	—	—
IPP impurity ^c	3.1	1.0	0.1
Ester impurity ^d	4.1	0.94	0.1
Any other individual impurity	—	1.0	0.1

^a *trans*-4-Isopropylcyclohexylcarboxylic acid.

^b *N*-(*trans*-4-Ethylcyclohexylcarbonyl)-D-phenylalanine.

^c *N*-(*trans*-4-Isopropylcyclohexylcarbonyl)-D-phenylalanine-D-phenylalanine.

^d *N*-(*trans*-4-isopropylcyclohexylcarbonyl)-D-phenylalanine-ethyl ester.

• LIMIT OF NATEGLINIDE RELATED COMPOUND B

Mobile phase: 0.77 g/L of ammonium acetate in methanol [NOTE—The following solutions are stable for up to 48 h when stored in a refrigerator.]

Standard solution: 0.02 mg/mL of USP Nateglinide Related Compound B RS in methanol. [NOTE—Nateglinide related compound B is *N*-(*trans*-4-isopropyl-cyclohexylcarbonyl)-L-phenylalanine.]

System suitability solution: 10 mg/mL of USP Nateglinide RS and 0.02 mg/mL of USP Nateglinide Related Compound B RS in methanol

Sample solution: 10 mg/mL of Nateglinide in methanol

Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

Mode: LC

Detector: UV 220 nm

Column: 4-mm × 25-cm or 4.6-mm × 25-cm; 5-μm packing L72 (see *Chromatographic Reagents* under *Reagents, Indicators, and Solutions*)

Column temperature: 40°

Flow rate: 0.8 mL/min. [NOTE—The flow rate can be adjusted as needed to achieve a recommended retention time of nateglinide related compound B at about 25 min.]

Injection size: 10 μL

System suitability

[NOTE—The elution order is nateglinide related compound B, followed by the nateglinide peak.]

Samples: *Standard solution* and *System suitability solution*

Suitability requirements

Resolution: NLT 0.8 between nateglinide related compound B and nateglinide, *System suitability solution*

Relative standard deviation: NMT 5%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of nateglinide related compound B in the portion of Nateglinide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of nateglinide related compound B from the *Sample solution*
 r_S = peak response of nateglinide related compound B from the *Standard solution*
 C_S = concentration of USP Nateglinide Related Compound B RS in the *Standard solution* (mg/mL)
 C_U = concentration of Nateglinide in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 0.2%

• LIMIT OF NATEGLINIDE RELATED COMPOUND C AND PHENYLALANINE

Mobile phase, Standard solution, System suitability solution, Sample solution, and Chromatographic system: Proceed as directed in the *Assay*.

Diluted standard solution: Dilute the *Standard solution* with *Mobile phase* to obtain a solution having a known concentration of about 0.01 mg/mL of nateglinide.

Analysis

Samples: *Sample solution* and *Diluted standard solution*

Calculate the percentage of each specified impurity listed in *Table 2* in the portion of Nateglinide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of nateglinide from the *Diluted standard solution*

C_S = concentration of nateglinide in the *Diluted standard solution* (mg/mL)

C_U = concentration of Nateglinide in the *Sample solution* (mg/mL)

F = relative response factor of each individual impurity (see *Table 2*)

Acceptance criteria

Individual impurities: See *Table 2*.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Phenylalanine	0.2	1.5	0.2
Nateglinide <i>cis</i> -isomer ^a (related compound C)	0.9	0.97	0.2
Nateglinide	1.0	—	—

^a *N*-(*cis*-4-isopropylcyclohexylcarbonyl)-D-phenylalanine.

Total impurities: The sum of all impurities found in the tests for *Limit of Nateglinide Related Compound A and Other Impurities*, *Limit of Nateglinide Related Compound B*, and *Limit of Nateglinide Related Compound C and Phenylalanine* is NMT 0.5%.

SPECIFIC TESTS

Change to read:

- **LOSS ON DRYING** <731>: Dry a sample at 105° for 2 h: it loses •NMT 0.5%• (RB 1-Oct-2010) of its weight.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at room temperature.

• **USP REFERENCE STANDARDS** (11)

USP Nateglinide RS

(-)-*N*-[(*trans*-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine

$C_{19}H_{27}NO_3$ 317.42

USP Nateglinide Related Compound A RS

trans-4-Isopropylcyclohexylcarboxylic acid.

$C_{10}H_{18}O_2$ 170.2

USP Nateglinide Related Compound B RS

N-(*trans*-4-Isopropylcyclohexylcarbonyl)-L-phenylalanine.

$C_{19}H_{27}NO_3$ 317.4

USP Nateglinide Related Compound C RS

Nateglinide *cis*-isomer, *N*-(*cis*-4-isopropylcyclohexylcarbonyl)-D-phenylalanine.

$C_{19}H_{27}NO_3$ 317.4▲USP33